Open AccessA phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis
Author(s) -
Ann Logan,
Zsuzsangy,
Nicholas M. Barnes,
Antonio Belli,
Valentina Di Pietro,
Barbara Tavazzi,
Giuseppe Lazzarino,
Giacomo Lazzarino,
Lars Bruce,
Lennart Persson
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0267183
Subject(s) - tolerability , amyotrophic lateral sclerosis , medicine , adverse effect , neurotrophic factors , pharmacology , gastroenterology , disease , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom